RICHMOND, Va.--(BUSINESS WIRE)--July 24, 2003--Insmed Incorporated (Nasdaq:INSM) a leading developer of pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs, will announce second quarter financial results Thursday, July 31.
The Company will host a conference call on Thursday, July 31, at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Company management will conduct the call that will highlight the performance expectations of the company and the ongoing pivotal Phase III trial with rhIGF-I/rhIGFBP-3 in GHIS.
To participate in the conference call dial 800-838-4403 (domestic) or 973-317-5319 (international). The call will be webcast live through Insmed's corporate website: www.insmed.com.
A telephonic replay of the call will be available for one week at 800-428-6051 (domestic) or 973-709-2089 (international), passcode: 301801. A web replay of the call will be available through the corporate website beginning at 1:00 p.m.
About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases with unmet medical needs. For further information about Insmed and rhIGF-I/rhIGFBP-3, please visit the company's corporate website at www.insmed.com.
CONTACT: Insmed Incorporated Baxter Phillips, 804-565-3041
